1. Home
  2. Research
  3. Research Groups
  4. Pharmacoepidemiology

Pharmacoepidemiology

2024 Activity indicators

  • 1 public competitive project led: ISCIII
  • 2 private projects led
  • 1 contract with public agency led: AEMPS
  • 4 publications
  • IF: 15.60
  • Q1 publications: 4 (100%)
  • 2 book chapters
  • 1 technical document of Strategy on Stroke in the SNS
  • Evaluators at national institutions: 1 PI
  • Member of evaluation committee: 1 PI

Milestones

  1. Publication on the role of new antidiabetic drugs in the primary prevention of chronic kidney disease. Rodríguez A, Fernández B, Ortiz A, Gil M, Rodríguez S, Ruiz G, Fernández E, Ruilope LM, de Abajo FJ. Glucose-Lowering Drugs and Primary Prevention of Chronic Kidney Disease in Type 2 Diabetes Patients: A Real-World Primary Care Study. Pharmaceuticals. 2024;17(10): 1299. DOI:10.3390/ ph17101299.
  2. Participation of Dr. FJ de Abajo in the National Health System Stroke Strategy.
  3. Award to the best research work of the Spanish Society of Clinical Pharmacology: "Antiplatelet Drugs as chemopreventive agents for Digestive Cancer (AD-DC): A Cohort Study".
  4. Formalization of a new contract with the Spanish Agency of Medicines and Health Products for the financing of the PIELenRed consortium.
  5. Collaboration with the Digestive System Service of the Hospital U. de La Princesa and the Fundación Teófilo Hernando to carry out a project on the effectiveness of H. pylori treatment in primary care.

Bibliometrics

  Articles Accum. FI Mean  Articles Q1 or Q2 % in Q1 or Q2 Articles D1 % in D1
2020 9 87.17 9.69 9 67 1 11
2021 3 18.55 6.18 3 100 2 67
2022 11 62.89 5.72 9 82 2 18
2023 7 35.70 5.10 7 100 1 14
2024 4 15.60 3.90 4 100 0 0
  34 219.91 6.12 29 90 6 22

Networks and alliances